Does it strike anyone else that these ideas about proving generics are infringing on R-IT patents are just another attempt to justify holding or buying more AMRN? Every time something terrible happens to the stock people look for silver linings - in this case we may be just fooling ourselves into thinking that a silver lining exists. And even if this eventually becomes an actual provable case of infringement, it's probably going to take at least a couple years for proof that generics are infringing R-IT patents, they're not going to go from selling zero to a million scrips in a matter of months, will be supply constricted at first. And I still ask how you prove generics are infringing when insurance is what's driving the substitution.